Sildenafil improves exercise capacity in patients with cystic fibrosis: a proof-of-concept clinical trial

BACKGROUND: Exercise intolerance is a common phenotype observed in patients with cystic fibrosis (CF). Treatment with sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, has previously been shown to improve exercise capacity (VO(2) peak) in other patient populations. Thus, the present study sou...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Ther Adv Chronic Dis
Egile Nagusiak: Rodriguez-Miguelez, Paula, Ishii, Haruki, Seigler, Nichole, Crandall, Reva, Thomas, Jeffrey, Forseen, Caralee, McKie, Kathleen T., Harris, Ryan A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: SAGE Publications 2019
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6876159/
https://ncbi.nlm.nih.gov/pubmed/31803404
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040622319887879
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak